U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06375187) titled 'A Phase I Study on Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors' on April 16.

Brief Summary: A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors

Study Type: Interventional

Condition: * Solid Tumor

* Gynecologic Cancer

* Breast Cancer

* Gastrointestinal Cancer

* Lung Cancer

Intervention: Biological: Engineering Tumor Infiltrating Lymphocytes

A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrat...